TILS.L Share News (TILS)
TILS Share
TILS Share
TILS Share
TILS Share
TILS
TILS Share
TILS Broker
TILS Directors
TILS Financial
TILS
TILS Short
TILSMon, 03rd Dec 2018 11:51
LONDON (Alliance News) - Tiziana Life Sciences PLC on Monday said it completed patient enrollment in a Phase 2a trial of Milciclib in hepatocellular carcinoma.
The company explained that the study is a six-month trial to evaluate the tolerability and anti-tumor activity of its small molecule inhibitor, Milciclib, in liver cancer.
The company expects top line data from the trial in the second quarter of 2019.
Tiziana shares were trading up 6.3% at 67.50 pence each.
UK TRADING UPDATE SUMMARY: Tiziana Offering to Raise GBP57 Million
Read moreIN BRIEF: Tiziana Submits Covid-19 Patent Application For Foralumab
Read moreIN BRIEF: Tiziana Bolsters Board By Adding John Brancaccio
Read moreUK TRADING UPDATE SUMMARY: LoopUp Set To Beat Expectations For 2020
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: Tiziana Life Sciences Progressing On StemPrintER Demerger
Read moreIN BRIEF: Tiziana Seals Manufacturing Agreement With STC Biologics
Read moreUK WINNERS & LOSERS SUMMARY: TomCo Shares Double As It Cancels Placing
Read moreTiziana Granted US Patent For Oral Administration Of Foralumab
Read moreIN BRIEF: Tiziana Life Sciences Director Gregor MacRae To Step Down
Read moreTiziana Annual Loss Widens On Higher Costs, Outlines Busy 2020
Read more
(Sharecast News) - Tiziana Life Sciences announced an extension to the current 'at the market sales agreement' with ThinkEquity, a division of Fordham Financial Management, on Friday.
Read moreUK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreTiziana Life Sciences Files Patent For Coronavirus Treatment
Read more
